Markets:

Overview

News

Currencies

International

Treasuries

Nkarta, Inc. - Common Stock (NQ:NKTX)

2.330 -0.030 (-1.27%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Nkarta, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Stocks That Hit 52-Week Lows On Thursday ↗

September 07, 2023

On Thursday, 283 companies set new 52-week lows.

Via Benzinga

The Latest Analyst Ratings for Nkarta ↗

August 10, 2023

Via Benzinga

Analyst Expectations for Nkarta's Future ↗

June 27, 2023

Via Benzinga

SVB Leerink Picks This Well-Positioned NK Cell-Focused Stock, Sees 117% Upside ↗

July 18, 2022

Via Benzinga

3 Hidden Penny Stocks That Could Turn $100 into $10,000 ↗

July 31, 2023

These penny stocks have multibagger upside potential with great margins of safety, according to Wall Street analysts.

Via InvestorPlace

Stocks That Hit 52-Week Lows On Wednesday ↗

July 05, 2023

Wednesday's session saw 43 companies set new 52-week lows.

Via Benzinga

NKX101's Leukemia Setting Phase 1 Results a Setback for Nkarta: Analyst Lowers Price Target Amid Revised Development Timeline ↗

June 27, 2023

Nkarta Inc (NASDAQ: NKTX) announced updated data from the Phase 1 study of NKX101 to treat patients with relapsed or refractory (r/r)

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 27, 2023

Via Benzinga

Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 27, 2023

Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.

Via Benzinga

Nkarta's Updated Data From Leukemia Study Fails To Cheer Investors ↗

June 27, 2023

Nkarta Inc (NASDAQ: NKTX) announced updated data from the Phase 1 study of NKX101 to treat patients with relapsed or refractory (r/r)

Via Benzinga

Why Shares of Nkarta Are Slumping Tuesday ↗

June 27, 2023

The pharmaceutical stock dropped after announcing so-so clinical trial results.

Via The Motley Fool

7 Stocks With Promising Upside Potential for 100% Returns ↗

May 07, 2023

If you still want to gamble even during this market environment, these are the stocks with 100% upside potential.

Via InvestorPlace

3 Biotech Stocks to Watch for Potential Breakthroughs ↗

April 11, 2023

These biotech stocks have significant upside and realistic breakthrough chances in the current and distant future.

Via InvestorPlace

NVIDIA To Rally Around 19%? Here Are 10 Other Analyst Forecasts For Friday ↗

March 17, 2023

Wells Fargo raised the price target for Warner Bros. Discovery, Inc. (NASDAQ: WBD) from $13 to $20. Wells Fargo analyst Steven Cahall upgraded the stock from Equal-Weight to Overweight. Warner Bros....

Via Benzinga

EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank? ↗

January 03, 2023

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022 ↗

December 22, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

December 08, 2022

During Thursday's trading, 138 companies set new 52-week lows.

Via Benzinga

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

December 06, 2022

By Ernest Dela Aglanu, Benzinga

Via News Direct

VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday ↗

December 05, 2022

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Nkarta Stock (NKTX) Is Volatile During Monday's Session? ↗

December 05, 2022

Nkarta Inc (NASDAQ: NKTX) shares are trading lower by 5.82% to $8.09, reversing after trading higher during the pre-market session, after the company announced updated data from its Phase 1 dose...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

December 05, 2022

The biggest pre-market stock movers for Monday include many Chinese shares that traders will want to keep an eye on today!

Via InvestorPlace

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers ↗

October 25, 2022

Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.

Via Benzinga

7 Unknown Biotech Stocks That Could Rocket in 2023 ↗

September 23, 2022

Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.

Via InvestorPlace

Cowen Slashes Price Target On This Stock By Over 78%; Also Check Out Some Other Big PT Changes ↗

August 12, 2022

Cowen & Co. cut the price target for The RealReal, Inc. (NASDAQ: REAL) from $14 to $3. RealReal shares fell 0.7% to $3.1388 in pre-market trading.

Via Benzinga

Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments? ↗

June 14, 2022

Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022 ↗

July 28, 2022

Via Benzinga

Positive Clinical Results Put Nkarta Stock on the Fast Track ↗

May 09, 2022

NKTX stock is a fast mover, and a recent share-price bump came in the wake of exciting data from a "killer cell" anti-cancer research program.

Via InvestorPlace

Executives Buy More Than $32M Of 3 Stocks ↗

May 02, 2022

Although US stocks closed sharply lower on Friday, there were a few notable insider trades.

Via Benzinga

How Is The Market Feeling About Nkarta Inc. - Common Stock? ↗

April 27, 2022

Nkarta Inc. - Common Stock's (NASDAQ:NKTX) short percent of float has risen 8.05% since its last report. The company recently reported that it has 1.84 million shares sold short,...

Via Benzinga

71 Biggest Movers From Yesterday ↗

April 27, 2022

Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Nkarta, Inc. - Common Stock (NQ:NKTX)

Headline News about Nkarta, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today